

ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Symptoms of TAK patients with and without SIE at diagnosis

Features	With SIE n=15	Without SIE n=37	p-value
Presenting symptoms			
Systemic Symptoms	10 (67)	32 (87)	0.17
Fatigue	6 (40)	17 (46)	0.77
Weight loss > 5kg	0	8 (22)	0.07
Fever	1 (7)	4 (11)	0.66
Night sweats	3 (20)	3 (8)	0.25
Rheumatic	6 (40)	17 (46)	0.69
Arthralgia	5 (33)	10 (27)	0.70
Myalgia	1 (7)	7 (19)	0.31
Ocular	3 (20)	5 (14)	0.56
Amurosis fugax	1 (7)	0	0.11
Episcleritis	1 (7)	2 (5)	0.86
Optic neuritis	0	1 (3)	0.52
Neurologic	5 (33)	12 (32)	0.92
Stroke	2 (13)	0	0.02
TIA	3 (20)	0	0.005
Light-Headedness	1 (7)	3 (8)	0.86
Headache	2 (13)	12 (32)	0.95
Seizure	0	1 (3)	0.52
Cognitive impairment	1 (7)	0	0.11
Cranial nerve palsy	0	1 (3)	0.52
Cardiovascular	15 (100)	37 (100)	1.00
Myocardial infarction	5 (33)	0	0.0002
Ischemic cardiomyopathy	1 (7)	0	0.11
Non-ischemic cardiomyopathy	1 (7)	2 (5)	0.85
Angina	2 (13)	0	0.02
Syncope	1 (7)	4 (11)	0.6
Hypertension	3 (20)	15 (41)	0.16
Blood pressure discrepancy	10 (67)	24 (65)	0.9
Arrhythmia	0	2 (5)	0.35
Congestive Heart Failure	0	1 (3)	0.52
Valvular Disease	3 (20)	4 (11)	0.37
Arterial Thrombosis	3 (20)	3 (8)	0.52
Venous Thrombosis	0	1 (3)	0.22
Claudication	7 (47)	17 (46)	0.96
Cutaneous	7 (47)	4 (11)	0.004
Ischemic limb	4 (27)	0	0.001
Rash	0	1 (3)	0.52
Purpura, petechiae	0	0	N/A

Raynaud's	1 (7)	0	0.11
Oral ulcers	2 (13)	2 (5)	0.35
Livedo reticularis	2 (13)	0	0.02
Gastrointestinal	1 (7)	1 (3)	0.50
Abdomen pain	1 (7)	2 (5)	0.86
Genitourinary	0	1 (3)	0.52
Respiratory	5 (33)	4 (11)	0.05
Dyspnea	5 (33)	2 (5)	0.007
Vascular Involvement			
Carotid*	6 (40)	27 (73)	0.03
Aorta	10 (67)	28 (76)	0.51
Subclavian*	8 (53)	30 (81)	0.04
Mesenteric (celiac, SMA, IMA)	6 (40)	11 (30)	0.48
Renal	5 (33)	12 (32)	0.92
Pulmonary	0	5 (14)	0.14
Coronary [†]	5 (33)	0	
Upper extremity	4 (27)	8 (22)	0.69

Data are presented as numbers (%).

*For patients with stroke or TIA, 4/5 (80%) had carotid and subclavian involvement ($p > 0.05$) compared to patients without SIE

[†]The only patients undergoing coronary artery imaging were those with SIE
SIE=severe ischemic events; TIA=transient ischemic attack

Supplementary Table 2. Imaging findings at follow-up in SIE and Non-SIE patients

Imaging at 6 months	With SIE n =5	Without SIE n=12	p-value
Unchanged lesions	1	4	0.58
Improved lesions	1	2	0.87
Worse lesions	3	6	0.71

Imaging at 12 months	With SIE n=2	Without SIE n=16	p-value
Unchanged lesions	1	10	0.73
Improved lesions	1	2	0.18
Worse lesions	0	4	0.42

Imaging at last follow up	With SIE n=5	Without SIE n=11	P-value
Unchanged lesions	4	8	0.76
Improved lesions	1	1	0.54
Worse lesions	0	2	0.31

Supplementary Table 3. Immunosuppressants use at follow-up in SIE and Non-SIE patients

Immunosuppressants use at diagnosis	With SIE n=15	Without SIE n=37	p-value
Methotrexate	4	6	0.43
Azathioprine	4	2	0.04
Mycophenolate mofetil	0	1	0.52
Cyclophosphamide	1	0	0.11

Immunosuppressants use at 6 months	With SIE n=15	Without SIE n=36	p-value
Methotrexate	6	17	0.71
Azathioprine	4	4	0.2
Mycophenolate mofetil	0	0	N/A
Cyclophosphamide	0	1	0.51

Immunosuppressants use at 12 months	With SIE n=13	Without SIE n=35	p-value
Methotrexate	8	19	0.6
Azathioprine	4	4	0.12
Mycophenolate mofetil	0	1	0.52
Cyclophosphamide	0	1	0.52
Leflunomide	0	1	0.52

Immunosuppressants use at last follow-up	With SIE n=13	Without SIE n=35	p-value
Methotrexate	5	8	0.31
Azathioprine	3	2	0.13
Mycophenolate mofetil	0	1	0.5
Cyclophosphamide	0	0	N/A
Leflunomide	0	4	0.18